- Sunday, 8 December 2019 |
- Today's FE |
- e-Paper
Published: November 14, 2019 14:58:36 | Updated: November 14, 2019 17:27:30
The government has banned the heartburn drug Ranitidine made with raw materials from two Indian companies after detecting high levels of cancer-causing ingredients in them.
The Directorate General of Drug Administration announced the move on Thursday.
The two Indian companies that supply the raw material – Ranitidine hydrochloride – are Saraca Laboratories Limited and Dr Reddy’s Laboratories, according to the DGDA, bdnews24.com reports.
Tests run on the raw materials from these companies and the finished product revealed higher than normal levels of N-nitrosodimethylamine (NDMA), which the US Food and Drug Administration says is a “probable human carcinogen, the authority said.
The drug authority has accordingly banned the production, sale and marketing of Ranitidine products made using the materials supplied by the Indian firms.
City Bank ties up with Indesore Sweater
Mercantile Bank, Zenith Islami Life Ins ink deal
Amari Dhaka brings a new Friday getaway
Agents to pay VAT for non-resident MNCs
Two in five jobs face risk of automation
India's central bank says all-day digital money transfer to be available
ICCB's conference on financing for sustainable development to begin Tuesday
Maruti Suzuki recalls over 60,000 vehicles across three brands
Pathao first major ride-sharing platform to get govt license
China Harbour celebrates Volunteers’ day with Mirsarai school students
Agents to pay VAT for non-resident MNCs
No project on front side of Kamalapur railway station: BR
13pc listed cos being traded below face value
Thieves steal onion from fields!
At least 43 die as fire engulfs factory in Delhi
Democrats huddle to draft impeachment charges
Stocks post modest gain in early trading
Shooting near Mexico’s presidential residence kills four
Heidelberg completes acquisition of Emirates Cement, Emirates Power
© 2017 - All Rights with The Financial Express
